Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: CME Group Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
CME Group Inc. May 14, 202685.9%
-
CME Group Inc. May 8, 202587.4%
-
CME Group Inc. May 9, 202486.5%
-
CME Group Inc. May 4, 202354.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 25, 2026 | CME Group Inc. | Grant or award | +645 | $225.00 | $145,125 |
| Jun 25, 2026 | CME Group Inc. | Grant or award | +422 | $225.00 | $94,950 |
| Jun 25, 2025 | CME Group Inc. | Grant or award | +879 | $273.03 | $239,993 |
| Jun 10, 2025 | CME Group Inc. | Open-market sale | −150 | $265.36 | $39,804 |
| Jun 10, 2025 | CME Group Inc. | Open-market sale | −350 | $265.35 | $92,873 |
| May 15, 2025 | CME Group Inc. | Open-market sale | −3,000 | $272.56 | $817,680 |
| Jun 25, 2024 | CME Group Inc. | Grant or award | +1,237 | $194.10 | $240,102 |
| Jun 13, 2024 | CME Group Inc. | Open-market sale | −3,000 | $195.44 | $586,320 |
| Oct 10, 2023 | CME Group Inc. | Open-market sale | −1 | $216.09 | $216 |
| Oct 9, 2023 | CME Group Inc. | Open-market sale | −1 | $215.76 | $216 |
| Oct 9, 2023 | CME Group Inc. | Open-market sale | −1 | $215.76 | $216 |
| Oct 6, 2023 | CME Group Inc. | Open-market sale | −1 | $211.93 | $212 |
| Jun 26, 2023 | CME Group Inc. | Grant or award | +1,342 | $178.89 | $240,070 |
Questions about Charles P. Carey
What boards is Charles P. Carey on?
Charles P. Carey sits on the board of CME Group Inc.
How long has Charles P. Carey served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.